DelveInsight’s “Open-Angle Glaucoma Pipeline Insight 2023” report provides comprehensive insights about key companies and pipeline drugs in the Open-Angle Glaucoma pipeline landscapes.
The report comprises Open-Angle Glaucoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Open-Angle Glaucoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Open-Angle Glaucoma pipeline products.
Open-Angle Glaucoma Overview
Open-angle glaucoma is a chronic, progressive, and irreversible multifactorial optic neuropathy that is characterized by an open angle of the anterior chamber, optic nerve head changes, progressive loss of peripheral vision, followed by central visual field loss. It is the most common type of glaucoma. Patients can suffer from it for years without knowing as it comes slowly and painlessly. Open-angle glaucoma usually happens to people over 50. There will be higher pressure in the eyes than the normal eyes, damaging optic nerves over time. As the nerve breaks down, one gets blind spots.
The risk increases with age and people over 50 years are at most risk, followed by one having a family history, and other conditions like diabetes, thin cornea, high blood pressure, and near-sightedness.
Some of the key takeaways from the Open-Angle Glaucoma Pipeline Report:
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Nova Eye Medical, New World Medical, Aurolab, Sight Sciences, Glaukos Corporation, Avedro Inc MicroSurgical Technology (MST), Santen Pharmaceutical, etc., are developing therapies for the treatment of Open-Angle Glaucoma.
Get an overview of pipeline landscape @ Open-Angle Glaucoma Clinical Trials Analysis
Open-Angle Glaucoma Key Players:
Scope of Open-Angle Glaucoma Pipeline Drug Insight
Table of Contents
1
Open-Angle Glaucoma Report Introduction
2
Open-Angle Glaucoma Executive Summary
3
4
Open-Angle Glaucoma- Analytical Perspective In-depth Commercial Assessment
5
Open-Angle Glaucoma Pipeline Therapeutics
6
Open-Angle Glaucoma Late Stage Products (Phase II/III)
7
Open-Angle Glaucoma Mild Stage Products (Phase II)
8
Open-Angle Glaucoma Early Stage Products (Phase I)
9
Open-Angle Glaucoma Preclinical Stage Products
10
Open-Angle Glaucoma Therapeutics Assessment
11
Open-Angle Glaucoma Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Open-Angle Glaucoma Key Companies
14
Open-Angle Glaucoma Key Products
15
Open-Angle Glaucoma Unmet Needs
16
Open-Angle Glaucoma Market Drivers and Barriers
17
Open-Angle Glaucoma Future Perspectives and Conclusion
18
Open-Angle Glaucoma Analyst Views
19
Appendix
20
About DelveInsight
Download a detailed sample report @https://www.delveinsight.com/sample-request/open-angle-glaucoma-pipeline-insight
Related Reports:
Open-Angle Glaucoma Market
DelveInsight’s ‘Open-Angle Glaucoma-Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Open-Angle Glaucoma Epidemiology
DelveInsight’s ‘Open-Angle Glaucoma Epidemiology Forecast to 2032′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +91-9650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
